title: [Eight years of experience with HIFU for prostate cancer: Oncological and functional results].
abstract: OBJECTIVE
  To study the oncologic and functional results of HIFU as a first-line treatment for localized prostate cancer.
  
  
  METHODS
  Enrolment of patients between 2006 and 2011 for the first treatment against localized prostate cancer with HIFU (Integrated Imaging(®), EDAP-TMS, Vaulx-en-Velin, France). The biochemical recurrence-free survival was calculated by using the Phoenix criterion (PSA>nadir+2 ng/mL). The functional complications were assessed clinically and through standardised questionnaires.
  
  
  RESULTS
  The condition of 191 patients was assessed at a mean follow-up of 55.5 ± 22.7 months. In 10,1% of the treatments, an incident during the medical procedure was observed with the volume of the prostate (P=0.026) as risk factor. The overall survival, the survival and the metastatic free survival rate were respectively 89.5%, 98.4% and 97.4%. The biochemical free survival rate for 5 years was 87.5%, 69% and 39% respectively for the low, medium and high-risk groups of d'Amico classification. Eighty-six percent of the patients with a PSA nadir ≤ 0.3 ng/mL were relapse free at 5 years. Whereas only 48% of the patients with a nadir>0.3 ng/mL did not. Only 17.8% of the patients had a rescue treatment with an average delay of 31.1 months. The urinary and sexual impairment was significant but 78.1% of the patients were dry at the end of the study. The most common complication found in 18.3% of the patients was the prostatic obstruction.
  
  
  CONCLUSIONS
  The oncologic and functional results of the HIFU seem similar to the other first-line treatments results and reveal that the HIFU is a therapeutic option for the treatment of prostate cancer in men over 70 years.
  
  
  METHODS
  5.
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. Electronic address: benjamin.rouget@chu-bordeaux.fr.
authors.forename: B
authors.initials: B
authors.lastname: Rouget
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Capon
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: J C
authors.initials: JC
authors.lastname: Bernhard
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Robert
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Ballanger
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Pierquet
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: H
authors.initials: H
authors.lastname: Bensadoun
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: J-M
authors.initials: JM
authors.lastname: Ferrière
authors.affiliation: CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Pasticier
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D015992:Body Mass Index; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D036761:Ultrasound, High-Intensity Focused, Transrectal / Q000379:methods
chemical_list: D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
keywords: Adverse effects; Cancer; Effets secondaires; High intensity focused ultrasound; Minimally invasive surgical procedures; Prostate; Thérapies mini-invasives; Ultrasons focalisés de haute intensité